Case-patient B, a nursing assistant at hospital I, exhibited a fever on March 17.
For all six emerging pathogens considered here, the majority of identified cases exhibited a fever.
She exhibited a fever on July 23 and on July 24 was depressed, intermittently recumbent, and periodically pawing, head pressing, and leaning against the wall.
A 63-year-old, HIV-negative woman was referred in June 2000 by a general practitioner to the outpatient pulmonary service because she had exhibited a fever and night sweats for 3 months.
Instead of generating a false positive for every patient exhibiting a fever but not having the flu, the more complex model would generate false positives only for patients having a larger number of factors similar to the symptomatic training set.
Study participants were considered to have B. miyamotoi sensu lato infection if they had exhibited a fever >37.5AC and a >4-fold rise in antibody to B. miyamotoi sensu lato GlpQ protein between acute- and convalescent-phase serum samples, as determined by ELISA and confirmatory Western blot assays for IgG alone or IgG plus IgM.
The patient exhibited a continuous fever followed by dyspnea 6 days after the third BCG treatment.
On August 6, she exhibited a high fever, chills, headache, arthralgia, and myalgia, with hypotension and was admitted to the hospital.
Only 5 of the 34 patients that were interviewed exhibited a significant fever (≥101.4°F) that required hospitalization.
Reducing the number of people exhibiting a high fever is essential in the proper treatment of malaria, and, ultimately, in the fight against Ebola.
